(HealthDay News) — The U.S. Food and Drug Administration has approved Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for active immunization against invasive meningococcal disease (IMD), ...

The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal ...

The FDA approved GSK’s pentavalent meningococcal vaccine to protect children and young adults aged 10 to 25 years against ...

Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...

GSK's Penmenvy wins FDA approval to protect against five meningococcal serogroups. The CDC panel will vote on usage ...

The studies confirmed that the vaccine has a safety profile consistent with the licensed meningococcal vaccines of GSK. The ...

The story has been updated to correct the FDA approval date to Friday, February 14 On Friday, February 14, the FDA approved ...

Penmenvy combines the antigenic components of Bexsero (meningococcal Group B vaccine) and Menveo (meningococcal Groups A, C, Y, and W-135 oligosaccharide diphtheria CRM197 conjugate vaccine).

Meningococcal Vaccine MarketThe global meningococcal vaccine market is experiencing significant growth, driven by rising ...

Thousands of U.S. health agency employees were terminated and told it was for poor performance, though they'd received strong ...

The CDC’s Advisory Committee on Immunization Practices is expected to provide recommendations on the appropriate use of Penmenvy at its meeting on February 26, 2025. The Food and Drug ...